We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CPI-613

News List

Rafael Pharmaceuticals Receives Fast Track Designation for CPI-613 americanpharmaceuticalreview
November 23, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer.
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 americanpharmaceuticalreview
November 11, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma.
Rafael Expands CPI-613 Trial americanpharmaceuticalreview
December 27, 2019
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia.
Rafael Pharma Signs License Agreement with Ono Pharmaceutical contractpharma
June 26, 2019
Aims to accelerate development and commercialization of cancer drug candidate CPI-613 (devimistat) in Japan and other Asian countries.